10X1000-TECH
1.4.2022 06:00:16 CEST | Business Wire | Press release
Fintech training platform 10x1000 Tech for Inclusion (“10x1000”) today released its results for 2021. With the vision to train 1,000 emerging talents and tech leaders each year for ten years, the platform saw a total of 1,067 learners from 66 countries and regions complete its Fintech Foundation Program and Fintech Leadership Program in 2021, and receive certifications from 10x1000 and the International Finance Corporation (IFC). Close to 80% of its learners are from South and Southeast Asia, with Bangladesh, Indonesia and the Philippines ranking as the top three countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331006106/en/
Mr. Jason Pau, Program Lead of 10x1000 said: “Deepening understanding of emerging technology applications, cross-region sharing and local networking are the top three priorities for learners embarking on 10x1000 programs. Realizing the potential for cross-country and cross-region knowledge sharing, 10x1000 has also focused on connecting and fostering a vibrant global fintech community of learners, experts and partners to cultivate learning. In 2021, 17 expert lecturers and 31 leading global organizations, tech investors, and industry organizations have joined the community as our close partners to collectively identify learners for 10x1000.”
“I encourage everyone in the financial ecosystem—including banks, fintechs, and regulators—to continue exploring development and market opportunities given the current fast-paced digitization and technological changes. Doing so will promote a balanced development that focuses on financial inclusion, consumer protection, cybersecurity, and digital financial literacy,” said Hans Koning, Global Chief Digital Finance Strategist at IFC. “Innovative programs like 10X1000 Tech for Inclusion are important to empower future digitization and tech leaders further increase their knowledge and skills to become drivers of sustainable innovation in emerging markets.”
On the back of a strong year, 10x1000 also announced a series of new and enhanced learning programs for 2022:
1. Fintech Expert Program
- The Fintech Expert Program will be introduced to further the learning journey for tech professionals.
- Through eight recorded video lectures, the program is designed to bring learners through a deep-dive into various topics ranging from AI, Blockchain to Cloud to gain practical knowledge and skillsets.
2. Green Fintech Miniseries
- To enhance awareness on ESG and green fintech, the miniseries will feature three recorded video lectures on real-life case studies and best practices.
3. Fintech Foundation Program in French
- To better meet the demand and reach more learners globally, 10x1000 will make its Fintech Foundation Program available in French.
Mr. Pau added: “We are committed to expand curriculums to provide a continuous and widely accessible learning journey for fintech and tech professionals worldwide. We sincerely welcome more experts and partners to join hands in our collective goal of bridging the digital skills gap and driving financial inclusion.”
Training content provided by 10x1000 is being guided by a Curriculum Steering Committee (CSC), an advisory body responsible for ensuring the quality and effectiveness of the curriculum. The current committee is composed of global experts from industry, academia, and international financial institutions.
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global fintech training platform that enables learners to become drivers of digital economic growth. Its mission is to train 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331006106/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom